Suppr超能文献

抗氧化剂与普瑞巴林联合使用对慢性胰腺炎导管清除术后疼痛复发的改善作用:一项随机、双盲、安慰剂对照试验的结果

Ameliorating effect of antioxidants and pregabalin combination in pain recurrence after ductal clearance in chronic pancreatitis: Results of a randomized, double blind, placebo-controlled trial.

作者信息

Talukdar Rupjyoti, Lakhtakia Sundeep, Nageshwar Reddy D, Rao G Venkat, Pradeep Rebala, Banerjee Rupa, Gupta Rajesh, Ramchandani Mohan, Tandan Manu, Murthy H Vivekananda

机构信息

Department of Medical Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, India.

Wellcome-DBT Laboratory, Asian Healthcare Foundation, Hyderabad, India.

出版信息

J Gastroenterol Hepatol. 2016 Sep;31(9):1654-62. doi: 10.1111/jgh.13332.

Abstract

BACKGROUND AND AIM

The aim of this study was to evaluate the effect of antioxidant-pregabalin combination on pain recurrence in patients with chronic calcific pancreatitis.

METHODS

In this randomized, double-blind, placebo-controlled trial, chronic calcific pancreatitis patients with pain recurrence following pancreatic ductal clearance of stones received either antioxidant-pregabalin combination or matching placebo for 2 months followed by open-label antioxidants for the next 4 months in both groups. Compliance, daily pain, and adverse events were recorded weekly and at the end of study by a coordinator blinded to treatment status. Primary outcome was pain improvement (visual analog scale and Izbicki score); secondary outcomes were as follows: complete pain resolution, painful days, and adverse events. Number needed-to-treat was calculated.

RESULTS

We randomized 42 and 45 patients (mean age 29.3 years) to treatment and placebo arms, respectively. Baseline characteristics, including pain scores, were similar for both groups. No patients received high-potency narcotic. At 2 months, a significant improvement in the treatment arm was observed in percent reduction of visual analog scale (-50 [-80.0; -32.1] vs -29.5 [-64.5; 0]; P = 0.01), Izbicki score (14.5 [0; 21.3] vs 30.0 [11.8; 41.3]; P = 0.001), complete pain resolution (20 [47.6%] vs 12 [26.7%]; P = 0.04), and number of painful days (10.0 [2.0; 16.0] vs 18.0 [7.0; 34.0]; P = 0.01). Needed-to-treat was 4.8. Pain reduction persisted at 6 months in the original treatment group (20.0 [15.0; 28.0] vs 36.0 [20.0; 50.0]; P = 0.006). A total of 33 patients in the treatment arm experienced mild to moderate self-limiting nausea/vomiting and drowsiness, respectively and did not require any change in study protocol.

CONCLUSION

Antioxidant-pregabalin combination results in significant relief in pain recurrence after ductal clearance in narcotic naïve patients with chronic calcific pancreatitis.

摘要

背景与目的

本研究旨在评估抗氧化剂 - 普瑞巴林联合用药对慢性钙化性胰腺炎患者疼痛复发的影响。

方法

在这项随机、双盲、安慰剂对照试验中,胰腺导管结石清除术后疼痛复发的慢性钙化性胰腺炎患者,一组接受抗氧化剂 - 普瑞巴林联合用药,另一组接受匹配的安慰剂,为期2个月,随后两组在接下来的4个月均接受开放标签的抗氧化剂治疗。由对治疗状态不知情的协调员每周记录并在研究结束时记录依从性、每日疼痛情况和不良事件。主要结局是疼痛改善(视觉模拟评分和伊兹比基评分);次要结局如下:疼痛完全缓解、疼痛天数和不良事件。计算需治疗人数。

结果

我们分别将42例和45例患者(平均年龄29.3岁)随机分配至治疗组和安慰剂组。两组的基线特征,包括疼痛评分,相似。没有患者接受强效麻醉药。在2个月时,观察到治疗组在视觉模拟评分降低百分比(-50 [-80.0;-32.1] 对 -29.5 [-64.5;0];P = 0.01)、伊兹比基评分(14.5 [0;21.3] 对 30.0 [11.8;41.3];P = 0.001)、疼痛完全缓解(20例 [47.6%] 对12例 [26.7%];P = 0.04)和疼痛天数(10.0 [2.0;16.0] 对18.0 [7.0;34.0];P = 0.01)方面有显著改善。需治疗人数为4.8。在最初的治疗组中,6个月时疼痛减轻情况持续存在(20.0 [15.0;28.0] 对36.0 [20.0;50.0];P = 0.006)。治疗组共有33例患者分别经历了轻度至中度的自限性恶心/呕吐和嗜睡,且无需对研究方案进行任何更改。

结论

对于未使用过麻醉药的慢性钙化性胰腺炎患者,抗氧化剂 - 普瑞巴林联合用药可显著缓解导管清除术后的疼痛复发。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验